Basic information Safety Supplier Related

HOE-140

Basic information Safety Supplier Related

HOE-140 Basic information

Product Name:
HOE-140
Synonyms:
  • HOE-140 (Icatibant)
  • HOE140; ICATIBANT;HOE 140
  • CS-1399
  • Firazyr
  • HOE 140 SYNTHETIC >99% SELECTIVE B2 BRAD YKIN
  • d-arg-l-arg-l-pro-l-hyp-gly-l-(2-thienyl)ala-l-ser-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2α,3β,7aβ)-octahydro-1h-indole-2-carbonyl-l-arg
  • Icatibant acetate, D-Arg-L-Arg-L-Pro-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carbonyl-L-Arg
  • HOE 140 Acetate
CAS:
138614-30-9
MF:
C59H89N19O13S.C2H4O2
MW:
1364.59
EINECS:
206-141-6
Mol File:
138614-30-9.mol
More
Less

HOE-140 Chemical Properties

storage temp. 
-20°C
solubility 
DMSO:65.0(Max Conc. mg/mL);47.63(Max Conc. mM)
Ethanol:0.25(Max Conc. mg/mL);0.18(Max Conc. mM)
PBS (pH 7.2):10.0(Max Conc. mg/mL);7.33(Max Conc. mM)
form 
A crystalline solid
More
Less

Safety Information

WGK Germany 
3
More
Less

HOE-140 Usage And Synthesis

Description

Although it is a rare disease, HAE is an autosomal dominant disorder that can be potentially life-threatening when swelling manifests itself within the upper airways. Antagonism of the constitutively expressed B2 receptor, therefore, would not only be beneficial in the treatment of HAE but also find application in inflammatory, allergic, and hyperalgesic disorders.Designed to possess enhanced metabolic stability with the inclusion of five non-proteinogenic amino acids, icatibant is a competitive and selective B2 receptor antagonist (devoid of activity against the inducible B1 receptor) with a Ki of 2.2±0.7 nM, and it is the first downstream targeting agent to receive regulatory approval. It joins purified C1 esterase inhibitor, danazol (an attenuated androgen), and tranexamic acid (an antifibrinolytic agent) as acute and prophylactic treatments for HAE.

Originator

Jerini (Germany)

Uses

Icatibant Acetate is a bradykinin B2 receptor antagonist that has been recently approved for treatment of acute attacks of hereditary angioedema (HAE).

Uses

Antagonist (bradykinin).

Definition

ChEBI: An acetate salt obtained by combining icatibant with acetic acid. Used for the treatment of acute attacks of hereditary angioedema in adult patients.

brand name

Metastat (CollaGenex);Firazyr.

Biochem/physiol Actions

B2 bradykinin receptors are present in the sensory neurons. Activation of B2 receptor by bradykinin is associated with pro-inflammatory, pain producing and cardiovascular responses. HOE-140 is a selective B2 bradykinin receptor antagonist. Presence of HOE-140 suppresses the effects of bradykinin and has been shown to have anti-hyperalgesic response, particularly towards inflammatory pain.

Synthesis

The peptidomimetic is prepared by standard solidphase technology on Wang resin employing Fmoc chemistry. Following trifluoroacetic acid cleavage with appropriate scavengers and HPLC purification, icatibant is ultimately isolated as its acetate salt.

HOE-140Supplier

Shaoxing Junyu Biotechnology Co., LTD Gold
Tel
0571-88211921 15572296305
Email
sales4@gotopbio.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
GL Biochem (Shanghai) Ltd
Tel
21-61263452 13641803416
Email
ymbetter@glbiochem.com
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Email
zhangsn@titansci.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com